MWNA
PRVL

Marshall Wace North America’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Marshall Wace North America’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-39,414
Closed -$520K – 1656
2019
Q2 		$520K Buy
+39,414
New +$574K ﹤0.01% 882

Other funds holding PRVL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace North America's PRVL Position: Q3 2019 in Review

Marshall Wace North America sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q3 2019, closing a stake of 39,414 shares — an estimated $520K sold.

Marshall Wace North America first reported a position in PRVL in Q2 2019 and held it in 1 quarter. The position peaked at $520K in Q2 2019. 42 funds tracked by Wall St. Rank hold PRVL as of Q3 2019.

  • Marshall Wace North America reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Marshall Wace North America sold 39,414 Prevail Therapeutics Inc. Common Stock shares in Q3 2019, an estimated $520K.
  • Marshall Wace North America first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Marshall Wace North America's Prevail Therapeutics Inc. Common Stock position peaked at $520K in Q2 2019.
  • 42 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q3 2019.

Based on Marshall Wace North America's 13F filing for Q3 2019, filed 14 Nov 2019.